PortfolioPath, jointly offered with Daniel Zweidler & Associates, helps senior management make crucial R&D investment decisions. It enables teams to understand technical uncertainty and commercial risk through the lens of clinical innovation. PortfolioPath can be applied to the entire R&D portfolio or to single therapeutic areas.

PortfolioPath tools:

• Use a consistent framework based on Equinox Group’s Disease Target Assessment tool to value programs, providing a valid basis to compare them
• Directly connect clinical claims to commercial potential, providing:
  • Insight into the attribute levels that drive value
  • The ability to measure how clinical uncertainty affects expected value and the probability of missing financial goals
• Shows how the addition of a program contributes to a portfolio’s value and reduces enterprise risk